Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06902350RecruitingPhase 1
Experimental drug CS231295 for advanced solid tumors
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06978920RecruitingPhase 1
Stem cell therapy for Parkinson's disease
This early-stage trial tests a new stem cell treatment called NCR201 for people with Parkinson's. It aims to see if the treatment is safe and might help improve symptoms.
Hefei, AnhuiAges 40–75 - NCT06969170RecruitingPhase 2
Psilocybin oral solution for generalized anxiety disorder trial
This study tests a psilocybin oral solution in adults with generalized anxiety disorder (GAD). It aims to see if the drug is safe, tolerable, and helpful for reducing anxiety symptoms.
Kingston, OntarioAges 18–60 - NCT06955988RecruitingPhase 1
Safety and early results of AST2303 for advanced lung cancer
This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06927466RecruitingPhase 1
B019 for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
BeijingAges 3–25 - NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06819657Recruiting
Remote ischemic conditioning after aneurysm surgery
This trial tests a safe, non-invasive treatment called remote ischemic conditioning (using a blood pressure cuff on your leg) to see if it helps brain recovery after aneurysm surgery. It might reduce secondary damage and improve outcomes.
Beijing, Beijing MunicipalityAges 18–80 - NCT06721143RecruitingPhase 1/Phase 2
Study of AION-301 for chronic kidney disease
This trial tests an experimental drug called AION-301 for people with chronic kidney disease (CKD). The goal is to see if it's safe and may help slow kidney decline. It's given by IV infusion and compared to a placebo (inactive infusion).
Miami, FloridaAges 35–75 - NCT06726369RecruitingPhase 1
Experimental drug for advanced solid tumors
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
Xiamen, FujianAges 18 years+ - NCT06719362RecruitingPhase 1
Testing a new cancer drug alone and with other therapies
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Portland, OregonAges 18 years+ - NCT06361108RecruitingPhase 1
Spray study for diabetic nerve pain in feet
This study tests a new spray medication (YJ001) applied to the feet to see if it is safe and helps reduce pain in people with diabetic peripheral neuropathy. You may qualify if you have diabetes, stable blood sugar, and moderate to severe nerve pain in your feet.
Fredericksburg, TexasAges 18–80 - NCT06672536RecruitingPhase 1/Phase 2
Study of SCT520FF for wet age-related macular degeneration
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
TianjingAges 45–80 - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06384352RecruitingPhase 1
Study of YL211 for advanced solid tumors
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Aurora, ColoradoAges 18 years+ - NCT06388707RecruitingPhase 1/Phase 2
Ultrasound therapy for drug-resistant temporal lobe epilepsy
This study tests if a new, non-invasive ultrasound treatment can safely reduce seizures in people whose seizures start in the temporal lobe and have not been controlled by at least two anti-epileptic drugs. The ultrasound is delivered through the scalp to gently stimulate the brain area where the seizures begin.
Palo Alto, CaliforniaAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06352359RecruitingPhase 1
Study of ONC 841 for advanced solid tumors
This phase 1 study tests an experimental drug called ONC 841 for people with advanced solid tumors that have not responded to other treatments. The trial aims to find a safe dose and see if the drug can shrink tumors.
Sacramento, CaliforniaAges 18 years+ - NCT06315738RecruitingPhase 1/Phase 2
Testing ST266 in Babies with NEC
This study tests an investigational drug called ST266 in babies with necrotizing enterocolitis (NEC), a serious gut infection. The goal is to see if it is safe and can help heal the bowel.
Little Rock, ArkansasAges 2 weeks–2 months - NCT06270316RecruitingPhase 1/Phase 2
Gene therapy for classic Fabry disease
This trial tests a one-time gene therapy called AMT-191 for men with classic Fabry disease who are still having symptoms despite enzyme replacement therapy. The goal is to see if it can reduce pain and stomach problems and improve overall health.
Birmingham, AlabamaAges 18–65 - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT05997615RecruitingPhase 1
Study of VIR-5500 for advanced prostate cancer
This trial tests VIR-5500 (AMX-500), a new targeted treatment, in men with prostate cancer that has spread and stopped responding to standard therapies. The goal is to see if it is safe and if it may help shrink or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT05773586RecruitingPhase 1
Study of a new medicine for anemia, first tested for safety
This Phase 1 trial tests how safe APG-5918 is, how the body processes it, and looks for early signs it may help people with certain types of anemia. It may include healthy volunteers and people with anemia, but the study is very selective to protect participants.
Guangzhou, GuangdongAges 18 years+ - NCT05710692RecruitingPhase 2/Phase 3
Study drug PRX-102 for Fabry disease in Japanese patients
This trial tests whether PRX-102 is safe and effective for treating Fabry disease in Japanese participants. It also measures how the drug moves through the body and affects body systems, to see if it helps your symptoms and organ function.
Chikushino-shi, FukuokaAges 13–70 - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.